JW Lifescience Corporation

Total Valuation

JW Lifescience Corporation carries a market capitalization of 181.79B, placing it among publicly traded companies globally. Its enterprise value stands at 224.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

JW Lifescience Corporation currently has 15.48M shares outstanding.

Valuation Ratios

JW Lifescience Corporation trades at a trailing price-to-earnings ratio of 6.66. The price-to-sales ratio is 0.77, and the price-to-book ratio stands at 1.02.

Enterprise Valuation

On an enterprise value basis, JW Lifescience Corporation trades at an EV/EBITDA multiple of 5.21 and an EV/FCF ratio of 5.07. The EV/Sales ratio of 0.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.21 provides insight into valuation relative to core operating earnings.

Financial Position

JW Lifescience Corporation maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

JW Lifescience Corporation posts a return on equity of 16.17 and a return on invested capital of 14.66.

Taxes

Over the trailing twelve months, JW Lifescience Corporation has paid 2.84B in income taxes, reflecting an effective tax rate of 8.86.

Stock Price Statistics

JW Lifescience Corporation's stock has declined approximately -5.32258% over the past 52 weeks. The 50-day moving average sits at 11,831.00, while the 200-day moving average is 12,878.25.

Income Statement

Over the trailing twelve months, JW Lifescience Corporation generated 252.72B in revenue and converted that into 29.19B in net income, yielding earnings per share of 1,885.04. EBITDA reached 43.06B, while operating income came in at 43.06B.

Balance Sheet

JW Lifescience Corporation holds 12.20B in cash and equivalents against 42.25B in total debt, resulting in a net debt position of 31.48B. Total book value stands at 190.67B, with working capital of 7.02B providing operational flexibility.

Cash Flow

JW Lifescience Corporation produced 30.54B in operating cash flow over the past twelve months. After subtracting -13.78B in capital expenditures, free cash flow totaled 16.76B - equivalent to 1,082.43 per share.

Margins

JW Lifescience Corporation operates with a gross margin of 28.87, reflecting its pricing power and cost economics. The operating margin of 17.04 and net profit margin of 11.55 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

JW Lifescience Corporation's most recent stock split took place on May 15, 2018 with a 1:2 split ratio.

Scores

JW Lifescience Corporation posts an Altman Z-Score of 3.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.